Insulin-like growth factor-1 and 17 beta-estradiol down-regulate prostate apoptosis response-4 expression in MCF-7 breast cancer cells

Imagem de Miniatura
Arquivos
art_CASOLARI_Insulinlike_growth_factor1_and_17_betaestradiol_downregulate_prostate_2011.PDF (496.9 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
CASOLARI, Debora A.
Citação
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, v.28, n.3, p.337-342, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The PKC apoptosis WTI regulator gene, also named prostate apoptosis response-4 (PAR-4), encodes a pro-apoptotic protein that sensitizes cells to numerous apoptotic stimuli. Insulin-like growth factor-1 (IGF-1) and 17 beta-estradiol (E2), two important factors for breast cancer development and progression, have been shown to down-regulate PAR-4 expression and inhibit apoptosis induced by PAR-4 in neuronal cells. In this study, we sought to investigate the mechanisms of regulation of PAR-4 gene expression in MCF-7 cells treated with E2 or IGF-1. E2 (10 nM) and IGF-1 (12.5 nM) each down-regulated PAR-4 expression in MCF-7 cells after 24 h of treatment. The effect of E2 was dependent on ER activation, as demonstrated by an increase in PAR-4 expression when cells were pretreated for 1 h with 1 mu M ICI-182,780 (ICI) before receiving E2 plus ICI. The effect of IGF-1 was abolished by pre-treatment for 1 h with 30 mu M LY294002 (a specific PI3-K inhibitor), and significantly inhibited by 30 mu M SB202190 (a specific p38MAPK inhibitor). We also demonstrated that E2 acts synergistically with IGF-1, resulting in greater down-regulation of PAR-4 mRNA expression compared with E2 or IGF-1 alone. Our results show for the first time that E2 and IGF-1 inhibit PAR-4 gene expression in MCF-7 cells, suggesting that this down-regulation may provide a selective advantage for breast cancer cell survival.
Palavras-chave
breast cancer, estrogen, estrogen receptor, prostate apoptosis response-4, insulin-like growth factor-1
URI
https://observatorio.fm.usp.br/handle/OPI/22884
Referências
  1. Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416
  2. Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
  3. Chung H, 2007, J ENDOCRINOL, V194, P77, DOI 10.1677/JOE-07-0073
  4. Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022
  5. El-Guendy N, 2003, EXP CELL RES, V283, P51, DOI 10.1016/S0014-4827(02)00016-2
  6. Bartucci M, 2001, CANCER RES, V61, P6747
  7. Chakraborty M, 2001, CANCER RES, V61, P7255
  8. SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457
  9. Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
  10. Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976
  11. Howell A, 2006, ENDOCR-RELAT CANCER, V13, P689, DOI 10.1677/erc.1.00846
  12. Altucci L, 1996, ONCOGENE, V12, P2315
  13. Nagai MA, 2008, MINI-REV MED CHEM, V8, P448, DOI 10.2174/138955708784223503
  14. Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016
  15. Gurumurthy S, 2004, J CELL BIOCHEM, V91, P504, DOI 10.1002/jcb.20000
  16. Nagai MA, 2010, INT J ONCOL, V37, P41, DOI 10.3892/ijo_00000651
  17. Kogel D, 2001, BRIT J CANCER, V85, P1801, DOI 10.1054/bjoc.2001.2158
  18. Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955
  19. Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
  20. Parkin DM, 2006, BREAST J, V12, pS70, DOI 10.1111/j.1075-122X.2006.00205.x
  21. Surmacz E, 2004, J EXP CLIN CANC RES, V23, P385
  22. Sells SF, 1997, MOL CELL BIOL, V17, P3823
  23. Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2
  24. El-Guendy N, 2003, MOL CELL BIOL, V23, P5516, DOI 10.1128/MCB.23.16.5516-5525.2003
  25. Boehrer S, 2001, Hematol J, V2, P103, DOI 10.1038/sj.thj.6200089
  26. Chan SL, 1999, J NEUROCHEM, V73, P502, DOI 10.1046/j.1471-4159.1999.0730502.x
  27. CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
  28. Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606
  29. Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488
  30. Goswami A, 2006, CANCER RES, V66, P2889, DOI 10.1158/0008-5472.CAN-05-4458
  31. Gurumurthy S, 2005, MOL CELL BIOL, V25, P1146, DOI 10.1128/MCB.25.3.1146-1161.2005
  32. Shrestha-Bhattarai T, 2010, ONCOGENE, V29, P3873, DOI 10.1038/onc.2010.141
  33. SISCI D, 2007, CURR PHARM DESIGN, V13, P1
  34. Stoll BA, 2002, ANN ONCOL, V13, P191, DOI 10.1093/annonc/mdf059
  35. Zhang S, 2005, J MOL ENDOCRINOL, V35, P433, DOI 10.1677/jme.1.01858

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24